Ansell Limited (ASX:ANN): FY26 Results, Surgical Glove Capacity and FY27 Priorities

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Ansell Limited (ASX:ANN): FY26 Results, Surgical Glove Capacity and FY27 Priorities

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ansell (ASX:ANN) reported FY26 sales of US$2,140.2 million, an increase of 6.8%.
FY26 adjusted EBIT reached US$321.9 million, while statutory net profit was US$208.6 million.
Operating cash flow rose to US$270.1 million, with net debt to adjusted EBITDA of 1.3 times.
Ansell opened a surgical glove manufacturing facility in India in September 2026.

Ansell Limited (ASX:ANN) manufactures personal protective equipment for healthcare and industrial workplaces, including surgical, examination, chemical-protection and mechanical-protection gloves. On 22 October 2026, the quoted share price was AUD 46.10, down 0.04% in the reported trading figures. Recent developments include the company’s FY26 results, a new manufacturing facility in India and plans to extend productivity and technology upgrades into FY27.

Company Business

Ansell operates through Healthcare and Industrial segments, supplying products used in hospitals, laboratories, cleanrooms, manufacturing and other workplaces. Its healthcare portfolio includes surgical gloves, examination and single-use products, and specialised cleanroom protection. Industrial offerings cover mechanical, chemical and body protection for a variety of occupational hazards. The company markets products internationally under brands including GAMMEX, MICROFLEX, HyFlex, AlphaTec and Ringers.

In FY26, Ansell (ASX:ANN) generated US$1,192.9 million in Healthcare sales and US$947.3 million from Industrial operations. Healthcare accounted for 56% of segment sales, with Industrial contributing 44%. The business serves customers across North America, Europe and other international markets, making manufacturing location, tariffs, freight and foreign-exchange movements relevant operational considerations.

Recent Development

In September 2026, Ansell inaugurated a manufacturing site in Kovai, India. The facility was already supplying the domestic market when announced, and additional capacity was planned for international markets. Its focus on surgical gloves extends the company’s manufacturing footprint. The site incorporates renewable-energy generation and water-recycling infrastructure.

Ansell also announced a second Ansell Xperience & Innovation Studio near Coimbra, Portugal, in September 2026. The facility adds a location for customer engagement and product-related work. During FY26, Ansell (ASX:ANN) continued its Accelerated Productivity Investment Program, reporting that its targeted US$50 million in recurring annual pre-tax savings had been achieved. The company identified enterprise-resource-planning upgrades as the next phase, beginning with North American commercial entities during FY27.

Financial Performance and Sector Context

For the year ended 30 June 2026, revenue rose 6.8% to US$2,140.2 million. Adjusted EBIT increased 14.1% to US$321.9 million, with the adjusted EBIT margin increasing from 14.1% to 15.0%. Statutory net profit after tax reached US$208.6 million, compared with US$101.6 million for FY25. Adjusted earnings per share were US148.6 cents. These adjusted measures exclude the significant items specified in company reporting.

Ansell (ASX:ANN) reported Healthcare adjusted EBIT of US$170.7 million and Industrial adjusted EBIT of US$170.6 million. In Healthcare, adjusted sales growth was 10.0% for Cleanroom and 6.4% for Surgical products. Industrial performance reflected mechanical-protection demand and higher sales in selected geographic and occupational markets. Demand for sterile products, workplace protective equipment and specialised gloves varies with customer activity and product requirements.

Operating cash flow, as defined by the company after specified investment, lease, interest and tax payments, reached US$270.1 million, compared with US$105.4 million a year earlier. Net debt to adjusted EBITDA was 1.3 times at year-end. Ansell reported US$752 million in combined cash and undrawn banking facilities and completed US$118.4 million of on-market buybacks during FY26. Its full-year dividend totalled US68.1 cents per share.

Risks to Consider

Import tariffs, manufacturing costs, raw-material and freight availability, and shifts in demand can influence product profitability. The company reported that sourcing changes and pricing actions offset higher US tariffs and additional costs associated with disruption in the Middle East during FY26. Future tariff changes and recovery of outstanding refunds remain uncertain. Foreign-currency movements and the execution of manufacturing and technology changes are additional considerations for Ansell (ASX:ANN).

What to Watch Next

Ansell’s FY27 adjusted earnings-per-share guidance is US158–170 cents, before significant items and excluding buyback effects. Management also outlined planned FY27 capital expenditure of US$45–55 million, approximately US$15 million of one-off pre-tax costs mainly relating to system implementation, and the continuation of its existing US$200 million share-buyback program. The company has scheduled its annual general meeting for 9 November 2026.

Key operational markers include the North American ERP rollout, additional production capacity in India, cleanroom demand, and the effects of price increases and sourcing actions. Investors can assess subsequent statements against the company’s published guidance rather than assuming any particular outcome.

Key Insights

Ansell (ASX:ANN) entered FY27 following higher FY26 sales, adjusted earnings and operating cash flow. Its recently opened Indian plant, changes to commercial systems and continuing productivity program form part of current operations. Financial leverage, tariff and cost exposure, product demand and progress against FY27 guidance remain measurable areas for subsequent reporting.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.